U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of Allergy and Infectious Diseases (NIAID) <http://www.niaid.nih.gov/>
For Immediate Release: Tuesday, May 14, 2013
CONTACT: NIAID Office of Communications, 301-402-1663, <e-mail:niaidnews@xxxxxxxxxxxxx >
RESULTS OF THE ROTAVAC ROTAVIRUS VACCINE STUDY IN INDIA
Statement of Anthony S. Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases
National Institutes of Health
We congratulate the Program for Appropriate Technology in Health (PATH), Bharat Biotech International, Ltd., and the scientists, government and people of India on the important results from the ROTAVAC rotavirus vaccine study <http://www.defeatdd.org/rotavac-clinical-trial-results>.
Highly contagious rotaviruses are the leading cause of severe diarrheal illnesses among infants and young children in both developed and resource-limited countries. Each year, rotavirus-induced diarrheal disease kills roughly 435,000 children younger than 5 years old and hospitalizes an estimated two million children worldwide, largely in developing countries. The youngest children -- those between 6 months and 2 years of age -- are most vulnerable.
Since 2006, two oral rotavirus vaccines have been licensed and available in North and South American, European and Eastern Mediterranean countries, where they have significantly reduced the burden of rotavirus-induced diarrhea. Based on that success, the World Health Organization recommended in 2009 the inclusion of rotavirus vaccine in all national immunization programs. However, access to vaccines can be slow and limited in the areas of the world where they are needed most.
ROTAVAC is a new rotavirus vaccine that consists of a strain of the virus that was isolated, manufactured and tested in India. The ROTAVAC trial represents a significant victory for India’s scientific community. Based on the study’s successful findings, infants in India will gain access to a licensed vaccine and its significant protection against severe rotavirus-induced gastroenteritis.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, was a partner in the public/private collaboration to develop and test this important vaccine. In the early 1990s, NIAID established an interagency agreement with the Centers for Disease Control and Prevention, and made several grant awards through the NIAID Indo-U.S. Vaccine Action Program.
These efforts fueled the early development and characterization of two neonatal non-disease-causing strains of Indian rotavirus (strains 116E and I321, respectively) as potential vaccine candidates. In 1997 and 1998, NIAID sponsored early clinical trials of the two vaccine candidates in healthy adults and healthy children. The studies were conducted at the Cincinnati Children’s Hospital, one of eight NIAID-funded Vaccine and Treatment Evaluation Units.
NIAID provided the 116E vaccine strain -- the particular strain tested in the ROTAVAC vaccine trial -- to Bharat Biotech through a technology transfer agreement in 2000. The company adapted the strain and produced the investigational vaccines for both animal and human clinical studies.
NIAID, with gift funds from PATH, further sponsored Indian investigators and their U.S. collaborators for three Phase I studies in India involving the live, attenuated (weakened) 116E rotavirus vaccine and provided clinical site monitoring for these trials. The results of these studies, which were conducted among adults, children ages 2 to 12 years, and infants ages 6 to 9 weeks, provided the basis for Bharat to further develop the vaccine. NIAID provided biostatistical vaccine development, regulatory affairs and clinical operations support for the later-stage clinical trials and sequenced the 116E strain’s genome in 2008.
We are deeply gratified to have played a role in establishing the safety and efficacy of the ROTAVAC vaccine. No infant or child should die as the result of rotavirus-induced severe diarrhea. NIAID is proud to be among the scientific partners who have worked over the past decades to potentially make that affliction a thing of the past for the children of India.
Additional information about the ROTAVAC study is available at <http://www.ClinicalTrials.gov> under the identifier NCT01305109 <http://www.clinicaltrials.gov/ct2/show/NCT01305109?term=NCT01305109&rank=1>.
Anthony S. Fauci, M.D., is Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Md.
NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at <http://www.niaid.nih.gov>.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
This NIH News Release is available online at: <http://www.nih.gov/news/health/may2013/niaid-14.htm>.
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
